Glenmark Pharmaceuticals had on Friday received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19.
FabiFlu will be used for treating COVID-19 patients with mild to moderate symptoms and will be made available from today evening and by next week across the country. The company has got approval under emergency category.
Each tablet of 200 mg costs ₹103 and a strip containing 34 tablets has been priced at ₹3500. It will be made available at hospitals and chemist shops and will be sold under medical prescription.